Background:Itk is considered an important target for anti-inflammatory drug discovery, particularly asthma. Results: We have designed an irreversible covalent inhibitor of the kinase by targeting Cys-442 in the ATP pocket. Conclusion: We have produced a potent, selective inhibitor with a long duration of action. Significance: We describe a novel drug discovery strategy with specific design features for inhaled delivery.